ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KYMR vs UNH // RETURN ON INVESTED CAPITAL (ROIC)

Kymera Therapeutics Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KYMR 5 — UNH 9
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYMR VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KYMR UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 0.00% 88.57% -88.57 UNH /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -21.40% 11.47% -32.87 UNH /roic <GO>
EV/EBITDA & P/E Valuation — 16.4x — TIE /valuation <GO>
Free Cash Flow Yield -2.30% 6.48% -8.78 UNH /fcf-yield <GO>
Operating Margin -60.00% 4.82% -64.82 UNH /operating-margins <GO>
Net Profit Margin 68.00% 3.14% +64.86 KYMR /net-margins <GO>
Revenue Growth (YoY) -16.70% 6.46% -23.16 UNH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.28% -2.28 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 3.12 +22.88 KYMR /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 UNH /piotroski-score <GO>
Options Implied Move & Put/Call Skew 6.70% 6.74% -0.04 KYMR /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 69.3 56.0 +13.28 KYMR /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.95 0.33 +0.62 KYMR /macro-sensitivity <GO>
Forward P/E Multiple 30.4x 17.1x +13.31 UNH /forward-pe <GO>
Enterprise Scale & Market Cap $10.19B $364.66B -$354.46B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KYMR REV UNH REV KYMR GROSS % UNH GROSS % KYMR FCF UNH FCF
FY 2025 $39.2M $447.57B 0.0% 88.7% -$234.3M $16.07B
FY 2024 $47.1M $400.28B 0.0% 88.3% -$207.3M $20.70B
FY 2023 $78.6M $371.62B 44.0% 89.6% -$106.4M $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYMR // BETA 0.95
UNH // BETA 0.33